Neutrophil elastase in bronchiectasis

Andrea Gramegna\textsuperscript{1}\textsuperscript{†}, Francesco Amati\textsuperscript{1}\textsuperscript{†}, Leonardo Terranova\textsuperscript{2}, Giovanni Sotgiu\textsuperscript{3}, Paolo Tarsia\textsuperscript{1}, Daniela Miglietta\textsuperscript{4}, Maria Adelaide Calderazzo\textsuperscript{5}, Stefano Aliberti\textsuperscript{1*} and Francesco Blasi\textsuperscript{1}

Abstract

The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclinical data and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF. In this context, NE seems to be a predictor of long-term clinical outcomes and a possible target of treatment. In order to better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence was performed. Two investigators independently performed the search on PubMed and included studies published up to May 15, 2017 according to predefined criteria. A final pool of 31 studies was included in the systematic review, with a total of 2679 patients. For each paper data of interest were extracted and reported in table.

In this review sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and during exacerbations and local or systemic antibiotic treatment. NE has also been associated with risk of exacerbation, time to next exacerbation and all-cause mortality. This study reviews also the role of NE as a specific target of treatment in bronchiectasis. Inhibition of NE is at a very early stage and future interventional studies should evaluate safety and efficacy for new molecules and formulations.

Keywords: Bronchiectasis, Neutrophil elastase, Protease, Neutrophil elastase inhibitors, Desmosine

Background

Neutrophil elastase

Neutrophils play a key role in the pathogenesis of numerous diseases, ranging from chronic inflammatory disorders to infectious diseases and neoplasms [1]. Their role in the innate immune system mainly consists in extracellular phagocytosis, involving reactive oxygen species, cationic proteins, and enzymes. Several granules are sequentially formed in neutrophil cytoplasm, differing in their propensity for exocytosis, according to their biosynthesis timing. Granules formed at a later stage of differentiation shows a higher secretory potential than those formed in immature myeloid cells, such as the azurophilic granules containing myeloperoxidase, defensins, and proteinases. Neutrophils live shortly in the blood of healthy individuals (around 8 h), but following inflammatory conditions they become activated and their longevity may increase up to 5 days. The prolonged life of neutrophils leads to functional changes and contributes to the inflammatory-associated morbidity shown in bronchiectasis patients [2].

Once inflammatory trigger develops in peripheral tissues, neutrophils are rapidly recruited toward to the anatomical site of inflammation. Their migration out of the blood stream involves endothelial attachment and rolling along the endothelium, activation, adhesion, and, finally, trans-endothelial extravasation into the interstitium. The neutrophilic inflammatory response depends on the degranulation of pre-formed mediators from cytoplasmatic granules and on the ability to generate respiratory burst activity via reactive oxygen species system. Although they ontogenetically play key functions in antimicrobial defense, their activation can also damage host cells and tissues. Neutrophil degranulation is responsible for the release of several inflammatory mediators, such as neutrophil elastase, cathepsin G, and proteinase 3 [3].

Human neutrophil elastase (NE) is a proteolytic enzyme belonging to the chymotrypsin-like family of the serine-proteinases. NE is a 218 aminoacid long protein packaged in cytoplasmatic azurophilic granules in neutrophil granulocytes [4]. Though NE is mainly involved...
in the response against bacteria, it can cause several detrimental effects, including extracellular matrix destruction, mucus gland hyperplasia and increased mucus production, reduction of ciliary beating rate, and direct damage to the airway epithelium [5–7]. The acid milieu within granules protects the cell from proteolytic activity. Upon neutrophil activation, degranulation is triggered by the mild alkalosis resulting from the fusion between the granules and cytoplasmic phagosomes containing engulfed bacteria [8]. In addition to this intracellular pathway, NE is also liberated into the extracellular space, both free and membrane-bound. High concentrations of soluble NE participate in bacterial killing at the site of degranulation and in a small area around the cell. More distantly, activated enzymes are completely neutralized by proteinase inhibitors. On the other hand, membrane-bound NE is remarkably resistant to inhibition by the anti-proteinase system, thus preserving its proteolytic activity. Overexpression of this mechanism has the potential to cause tissue damage [9].

During neutrophil activation, NE-containing granules also translocate from the cytoplasm to the nucleus, where it is involved in the degradation of chromatin by splitting histones. Then, neutrophils disintegrate and release neutrophil extracellular traps (NETs). Although this remains a controversial or fully unexplored area, this process is hypothesized to facilitate the neutralization of pathogens, including bacteria, fungi, and protozoa. NETs are networks of extracellular fibers, composed of DNA bound to histone proteins and neutrophil proteinases. NE is the most common non-histone protein in NETs [10].

A complex interaction among proteases and anti-proteases is required for an effective respiratory immune system. Lower airways in patients with neutrophil elastase-mediated lung diseases are characterized by an excess of proteases leading to tissue destruction and lung function decline. A1AT is the most abundant anti-protease within the lung and the major inhibitor of NE. A1AT is encoded by the SERPINA1 gene located on the long arm of chromosome 14 and produced mainly by hepatocytes and, to a lesser extent, by alveolar macrophages. Imbalance between NE and A1AT may be due to either an A1AT deficiency, as documented in COPD and emphysema, or unopposed NE activity, as proved in CF and bronchiectasis [11]. In the latter context, NE shows the ability to combine with polyanions (such as DNA or glycosaminoglycans) and syndecan-1 becoming inaccessible and limiting its inactivation by A1AT [12].

Besides NE, the serine protease group also includes cathepsin G (Cat G) and proteinase 3 (PR3), which are also stored in high concentrations in the azurophil granules within the neutrophil cytoplasm [4]. Cat G is a 235-amino acid protein released during the neutrophil activation process. Intracellularly, Cat G is released within the phagosome to degrade engulfed pathogens; extracellularly, it contributes to the degradation of structural ECM components and other immune mediators [13]. PR3 is a 222-amino acid long serine protease encoded by the PRTN3 gene and expressed by activated neutrophils. Its biological function is similar to that of NE. In particular, PR3 is responsible for proteolytic degradation and activation of IL-8 in a truncated peptide with fostered chemotactic effect towards neutrophils.

**NE determination assays**

Different techniques have been used for NE determination. Both ready to use commercial kits and in-home assays are useful for in vitro quantitative determination of NE. The three most used techniques are ELISA [14], fluorimetric [15] and spectrophotometric [16] methods. In Table 1 some example of NE determination assays is provided showing different samples, types of measurement and detection ranges.

NE can be detected by two different methods: the assessment of NE ability to proteolytically cleave a synthetic substrate (qualitative measurement); and the quantification of human NE concentrations in different biological media (quantitative measurement). Both the detection of the active enzyme and the measurement of the amount of enzyme bound to its inhibitor, alpha-1 antitrypsin (A1AT), are techniques currently used to measure NE in biological samples.

When ELISA assays are employed, the wells in a microtiter plate are coated with a specific antibody able to bind NE. ProteaseTag® is a quantitative method to dose NE activity using NE-Tag and the subsequent antibody step provides additional signal amplification with increased sensitivity with good results in a recent study conducted by Chalmers [17].

Fluorimetric and spectrophotometric assays are based on the ability of NE to proteolytically cleave a synthetic substrate causing the release of a fluorophore or a change in optical density, respectively, which can be quantified by fluorescence or absorbance microplate readers. Standard curves are obtained for both methods and concentration of samples can be determined from curve interpretation.

Commercial kits may also be used to quantify NE in plasma, serum, cell-culture supernatant, bronchoalveolar lavage (BAL), sputum, or whole blood. Among other methodologies, elastin agarose diffusion plate for measurement of elastolytic activity has been also reported in previous literature [18].

Elastin degradation as a consequence of NE activity results in the presence of elastin-derived peptides, including desmosine and isodesmosine in serum, plasma and urine. Both separation based on high performance
Definitions: NE neutrophil elastase, alpha1-PI alpha-1 proteinase inhibitor; PMN polymorphonuclear leukocytes

**Neutrophil elastase determination assays**

| Name | Samples | Type of measurement | Assay | Unit of measurement | N° of test | Detection range | Limit of detection |
|------|---------|---------------------|-------|---------------------|------------|-----------------|-------------------|
| Human Elastase ELISA (Hycult Biotech) | Plasma, Cell culture supernatant | Active NE | ELISA | ng/mL | 2 × 96 | 0.4–25 ng/mL | 0.4 ng/mL |
| ProteaseTag® Active NE Immunoassay (ProAxis Ltd) | BAL, Sputum sol, Serum free media | Active NE | ELISA | ng/mL | 96 | 15.625–1000 ng/mL | 7.2 ng/mL |
| Human PMN Elastase ELISA Kit (Abcam) | Cell culture supernatant, Serum, Plasma | PMN Elastase/alpha1-PI complex | ELISA | ng/mL | 96 | 0.16–10 ng/mL | 1.98 pg/mL |
| Neutrophil elastase Human ELISA Kit, CE (eBioscience) | Cell culture supernatant, Serum, Plasma | PMN Elastase/alpha1-PI complex | ELISA | ng/mL | 96 | 0.16–10.0 ng/mL | 1.98 pg/mL |
| Neutrophil Elastase Activity Assay Kit (Abcam) | Plasma, Whole Blood, Purified protein | Active NE | Fluorometric | ng | 100 | 1–25 ng | 1 ng |
| Dynatech MR 5000 (Dynatech Corporation) | Sputum sol | Active NE | Spectrophotometry | mcgM | 96 | – | – |
| Neutrophil Elastase Activity Assay Kit (Cayman Chemical) | Blood | Active NE | Fluorometric | mlU/mL | 2 × 96 | 0–10 mlU/mL | 0.156 mlU/mL |

**Cystic fibrosis**

An outburst of neutrophilic inflammation characterizes CF patients and it is associated with high concentrations of neutrophil proteases, including NE. NE has several implications in inflammation in CF, although a comprehensive summary of NE effects is not in the purpose if this review NE has an important role in the pathogenesis of lung inflammation in CF even in the absence of any infections. High levels of both NE and IL-8 have been demonstrated in BAL of infants with CF [22]. A recent study by Sly showed a correlation between NE activity in BAL from CF children and the early development of bronchiectasis [23].

NE is a potent upregulator of several inflammatory chemokines, such as IL-8 and MMP-9, leading to a self-perpetuating cycle of neutrophilic inflammation with several detrimental effects [24]. Firstly, NE impairs ciliary beating and promotes expression of respiratory tract mucins (MUC5AC and MUC5B), resulting in mucociliary clearance failure [7, 25]. Secondly, NE-dependent structural damage against elastin and other pulmonary components leads to the irreversible airway dilation and early bronchiectasis development. Thirdly, NE can degrade lactoferrin, an important anti-microbial glycoprotein as well as several molecules involved in pathogens’ opsonization [26–29]. Furthermore, NE can cause impairment of lymphocytic function by degradation of T-cell surface receptors and interfere with the process of antigen presentation by dendritic cells [30, 31]. The sum of all these mechanisms leads to the paradox of an over-stimulated immune system unable to effectively kill colonizing pathogens.

Finally, NE may directly affect the ion transport in CF cells acting as a potent activator of silent ENaC channels causing increased Na absorption and further airway surface dehydration and muco-ciliary dysfunction [32]. In a recent study, Le Gars and coworkers illustrated that high NE levels lead to CFTR loss of function via activation of intracellular calpains that are directly responsible for the proteolytic degradation of CFTR [33].

Treatments targeted against NE have been evaluated in CF patients. AZD9668, a reversible oral inhibitor of NE, when administered 60 mg twice daily orally for 4 weeks, showed no effect on sputum neutrophil counts, NE activity, lung function or clinical outcomes, but a consistent pattern of reduction in sputum inflammatory biomarkers and a significant decrease of free and total urine desmosine were reported in a double-blind randomized controlled trial (RCT) enrolling ~60 CF patients [34]. A phase-II clinical trial assessed the efficacy of inhaled A1AT, with significant reduction of NE activity and inflammatory biomarker expression without any effects on lung function [35]. The limited efficacy observed with both AZD9668 and A1AT in CF patients could be mainly ascribed to the fact that the studies were most likely too short and not powered to investigate disease-modifying effects.

**Chronic obstructive pulmonary disease**

In patients with COPD neutrophils in sputum correlate with severity of disease in terms of FEV1 decline and peripheral airway dysfunction identified by high-resolution computed tomography [36]. Several studies highlighted that cigarette smoke and lung pollutants activate macrophages and epithelial cells triggering the
release of neutrophil chemotactic factors [37, 38]. In this context NE is a major determinant of tissue damage. A landmark study on COPD-related lung tissue by Damiano showed a positive correlation between the distribution of NE within alveolar spaces and the presence of emphysema [39]. Instillation of human NE has been shown to induce emphysema in the animal model, while Shapiro and coworkers demonstrated that mice deficient for NE expression were protected from the development of emphysematous changes [40, 41]. More recently, Paone have found that elevated levels of NE in COPD in both sputum and BAL highly correlated with severity of disease and lung function decline [42].

Treatment strategies targeting NE have been proposed also for patients with COPD. AZD9668 was shown to slow lung function decline and dampen the inflammatory burden [43]. However, two RCTs which recruited symptomatic COPD patients exposed to AZD9668 for 12 weeks failed to show any clinical efficacy nor beneficial effects on inflammatory biomarker expression [44, 45]. This lack of efficacy may be due to inappropriate study design in terms of patients selection, relevant dose, duration of treatment and endpoints assessments. It has been recently demonstrated that in a subpopulation with alpha1-antitrypsin (A1AT) deficiency, intravenous administration of A1AT slowed the loss of lung parenchyma [46].

Asthma
Chronic inflammation in asthma is highly heterogeneous. Although in the past asthma was thought as a mere Th2-mediated inflammatory response to inhaled antigens, neutrophils and their products have recently been considered to play a role during both stable conditions and exacerbations [47, 48]. Simpson and colleagues showed that neutrophilic asthma is characterized by higher concentrations of active NE, generating the hypothesis that anti-proteases may be beneficial in the treatment of asthmatic patients [49]. At the current state, no studies on NE inhibitors in patients with asthma are currently available.

Neutrophil Elastase in Bronchiectasis
Bronchiectasis is defined as an abnormal and permanent dilation of the bronchi associated with daily cough, sputum production, and recurrent respiratory infections [50]. The prevalence of bronchiectasis has risen during the last decade both in hospital and community settings owing to population aging, as well as widespread use of chest CT scan and more awareness of the disease [50, 51]. The pathophysiology of bronchiectasis is not completely understood, particularly in view of the heterogeneity of the disease and the absence of an animal model [52]. A fundamental role is played by both impaired mucus clearance and chronic bacterial infections leading to a serious neutrophilic activation by the release of chemotactic mediators. A recent study by Dente and coworkers demonstrated that sputum neutrophils in bronchiectasis patients correlated with worse pulmonary function, bacterial colonization, and severe disease [53]. In this context, NE is a key determinant of tissue damage and a potential marker of both disease severity and activity, a predictor of long-term clinical outcomes, and a treatment target. In order to better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence on NE in bronchiectasis was performed.

Methods
Search methodology
Two investigators (AG and FA) independently performed the search on PubMed and assessed the studies according to predefined criteria. Reference lists of the selected manuscripts were also manually assessed. English language restriction was applied. This systematic revision was conducted according to PRISMA statement [54].

Study selection
We included studies published up to May 15, 2017. Key terms included: ‘bronchiectasis AND neutrophilic elastase OR neutrophil elastase’; ‘bronchiectasis AND protease’; ‘bronchiectasis AND neutrophil elastase inhibitors’; ‘bronchiectasis AND desmosine’. After literature search, titles and abstracts were reviewed by two independent investigators (AG and FA) and in case of disagreement a final decision was taken by the principal investigator (SA). Articles were excluded if: (1) written in languages other than English; (2) they were case reports, case series, or qualitative reviews; (3) NE was not measured; (4) missing bronchiectasis patients; (5) inclusion of CF patients; (6) inclusion of pediatric patients; (7) full-text was unavailable. Full-text was finally obtained for selected papers.

Data extraction and analysis
After the full-text analysis, data of interest from each included paper were extracted. Data of interest included: name of the first author, year of publication, study design, sample size, assay manufacturer, biological matrix, setting, clinical state of patients, quantitative findings and endpoints. Corresponding authors were contacted if data were not present or unclear in the full-text. Given the high degree of heterogeneity across papers taken into account, a meta-analysis was not performed.

Results
The process and results of the search are shown in Fig. 1. The majority of the selected studies were rejected because either they were qualitative reviews or case
series \((n = 35)\) or not dealing with bronchiectasis patients \((n = 34)\), or evaluating CF patients \((n = 29)\) /children \((n = 5)\), or their full-text was not available in English \((n = 16)\). A final pool of 31 studies was included in the systematic review, with a total of 2679 patients (Table 2). Selected papers were published from 1984 to 2016, with an elevated frequency in the period 1998–2002 \((10/31, 32.3\%)\). The majority had a cross-sectional design \((19/31, 61.3\%)\). Only six \((19.4\%)\) studies included patients during an acute exacerbation. Measurement of NE was highly heterogeneous, including both commercial kits and in-home assays. Sputum was the most represented biological sample for NE detection. Blood samples were occasionally collected for NE or desmosine measurement \([17, 21, 55]\). Only one \((3.2\%)\) study detected urine desmosine. Most of the selected studies were aimed to assess NE as an inflammatory marker \((19/31, 61.3\%)\), while 7 \((22.6\%)\) studies investigated NE as a marker of response to treatment and 1 \((3.2\%)\) study evaluated NE as a target of therapy.

**Discussion**

Clinical relevance of NE role in bronchiectasis has been addressed according to a multidimensional approach: its use as inflammatory biomarkers; potential indicator of severity of disease; predictor of clinical outcomes or response to treatment; target of treatment.

**NE as an inflammatory marker**

Patients with clinically stable bronchiectasis exhibit a permanent neutrophilic activation in the airways and display higher sputum levels of NE and others inflammatory mediators than healthy subjects \([56–58]\). Because of the presence on NE-positive neutrophils in the *lamina propria*, the inflammation is assumed to be driven by NE \([59]\).

Fujita and Chan demonstrated in different studies that serum levels of NE-A1AT complex in patients with bronchiectasis were significantly higher in comparison to those of healthy subjects suggesting that lung injury is mainly due to NE overexpression than anti-proteinase system deficiency \([12, 60, 61]\).

Angrill proposed that airway inflammation is permanent and may occur even in the absence of bacterial colonization, as demonstrated by the increase of NE and other inflammatory mediators in the BAL of 49 patients in comparison with healthy subjects \([62]\). Previous studies reported that purulent sputum was associated with NE concentration, and can be considered a marker for proteolytic and inflammatory activity \([18, 63–65]\). These findings were consistent with recent data reported by Goeminne who demonstrated a strong correlation between sputum purulence and proteolytic enzymes, both of which seem to predict the degree of inflammation and disease severity in bronchiectasis \([66]\).
### Table 2: Results of the systematic review

| Author and year | Study design | Setting | Clinical stability | Sample size | Assay manufacturer (methods) | Quantitative findings | Biological matrix | Major results |
|-----------------|--------------|---------|--------------------|-------------|------------------------------|-----------------------|-------------------|---------------|
| Stockley, 1984  | Cross-sectional | Monocentric, outpatients | Stable state Exacerbation | 34 Bx patients | Elastin-agarose diffusion plate (in-home assay) | NE activity (μg x mL): grade1 19.5; grade2 48.2; grade3 62.9 | Sputum | Correlation with sputum macroscopic appearance |
| Smallman, 1984  | Cross-sectional/ Prospective | Monocentric, outpatients | Stable state | 8 Bx patients | Elastin-agarose diffusion plate (in-home assay) | NE activity (μg x mL): not quantified but evaluated as present/not present (lower limit of detection 0.8) | Sputum | Inverse correlation with ciliary beat frequency, NE reduction after short-term antibiotic therapy |
| Fujita, 1992    | Cross-sectional | Monocentric, outpatients | Stable state | 9 Bx patients in a cohort of 64 chronic respiratory diseases + 15 healthy subjects | Elisa for NE- A1AT complex (in-home assay) | NE-A1AT complex levels (μg x L): 558 ± 198; healthy subjects 122 ± 4 | Blood | NE-A1AT complex higher in Bx patients than in healthy subjects |
| Lloberes, 1992  | Cross-sectional | Monocentric, outpatients | Stable state | 26 Bx patients | Elastin-agarose diffusion plate (in-home assay) | NE activity (μg × 100 μL): purulent 7.75 (0–21.5); mucopurulent 1.3 (0–19.5); mucoid 0 | Sputum | Correlation with sputum macroscopic appearance |
| Ip, 1993        | Prospective   | Monocentric, outpatients | Exacerbation | 12 Bx patients | Spectrophotometry, SLAPN substrate | NE activity (mU × 100 μL): baseline 50.5 ± 17.1; exacerbation before atb 51.8 ± 25.4; 1-week after 24.3 ± 20.7; 2-week after 35.1 ± 17.8; 2-week after atb −12.1 ± 15.6; 6-week after atb −32.8 ± 26.8 | Sputum | NE reduction after short-term antibiotic therapy |
| Llewellyn-Jones, 1995 | Prospective | Monocentric, outpatients | Stable state | 9 Bx patients + 8 healthy subjects | Fluorescence (in-home assay) | NE activity (μg x mL): day −7th 4.0 ± 0.46; baseline 4.15 ± 0.69; day 14th 4.25 ± 0.63; day 28th 4.39 ± 0.65; day 63th 4.03 ± 0.67 | Blood | No NE reduction after indomethacin |
| Sepper, 1995    | Cross-sectional | Monocentric, outpatients | Stable state | 24 Bx patients + 15 healthy subjects | Spectrophotometry, SAAVNA substrate | NE activity (mU x g): mild group 0.21 ± 0.09; moderate group 1.87 ± 1.12; severe group 2.64 ± 1.63; healthy subjects 0.09 ± 0.03 | BAL | Correlation with symptoms, exacerbation rate and radiological severity |
| Nakamura, 1997  | Cross-sectional | Monocentric, outpatients | Stable state | 3 Bx patients in a cohort of 8 chronic respiratory diseases + 15 healthy subjects | Elisa (in-home assay) | Quantitative findings only reported as figures | BAL | NE higher in Bx than in healthy subjects |
| Gaga, 1998      | Cross-sectional | Monocentric, outpatients | Stable state | 12 Bx patients + 11 healthy subjects | Immunocitochemistry (in-home assay) | Neutrophils (cells x mm³): Bx patients 114 healthy subjects 41 | Biornchial biopsies | NE higher in Bx than in healthy subjects |
| Nakamura, 1999  | Prospective   | Monocentric, outpatients | Stable state | 3 Bx patients in a cohort of 10 chronic respiratory diseases | Elisa (in-home assay) | NE levels (μg x mL): baseline 125.5 ± 47.5; 16.8 ± 7.1 after atb | BAL | NE reduction after 3-month roxithromycin |
| Ichikawa, 1999  | Cross-sectional | Monocentric, outpatients | Stable state | 18 Bx patients in a cohort of 39 chronic respiratory diseases + 28 healthy subjects | Spectrofluorometry, AMC substrate | NE activity (μL): purulent 1239.2 ± 1017.8; mucoid 45.7 ± 115.1 | Sputum | Inverse correlation with IgBF levels and sputum purulence |
| Hill, 2000      | Cross-sectional | Monocentric, outpatients | Stable state | 43 Bx patients in a cohort of 160 chronic respiratory diseases | Spectrophotometry | NE levels (nM): mixed flora 0 (0–20); high bacterial load 21 (4–48) | Sputum | Correlation with sputum bacterial load |
| Author and year | Study design | Setting | Clinical stability | Sample size | Assay manufacturer (methods) | Quantitative findings | Biological matrix | Major results |
|----------------|--------------|---------|--------------------|-------------|-----------------------------|----------------------|-------------------|---------------|
| Schaan, 2000 [68] | Cross-sectional | Monocentric, outpatients | Stable state | 11 Bx patients in a cohort of 66 chronic respiratory diseases +12 healthy subjects | Immunoluminometry Colorimetry | NE-A1AT complex levels (ng x mL): Bx patients 44 (15–152); healthy subjects 3 (0–15) | BAL | NE higher in Bx than in healthy subjects; Correlation with P. aeruginosa chronic respiratory infection |
| Tsang, 2000 [75] | Cross-sectional | Monocentric, outpatients | Stable state | 30 Bx patients | Spectrophotometry, SAAVNA substrate | NE levels (U x mL): 6.60 ± 3.13 | Sputum | Correlation with 24 h sputum volume, sputum inflammatory markers (leukocytes, IL-8 and TNFα), radiological severity and spirometry (FEV1, FVC) |
| Zheng, 2000 [69] | Cross-sectional | Monocentric, outpatients | Stable state | 35 Bx patients + 18 healthy subjects | Spectrophotometry, SAAVNA substrate | NE levels (Unit x mL-1): P. aeruginosa 222.6 (18.3–267.5); 8.7 (0.6–186.7) | Sputum | Correlation with P. aeruginosa chronic respiratory infection |
| Viglio, 2000 [21] | Cross-sectional | Monocentric, outpatients | Stable state | 13 Bx patients in a cohort of 54 chronic respiratory diseases +24 healthy subjects | HPCE | DES (μg x g creatinine-1): Bx patients 223.6 (18.3–267.5); 8.7 (0.6–186.7) | Urine | Desmosine higher in stable Bx than in other chronic respiratory disease and healthy subjects |
| Angrill, 2001 [62] | Cross-sectional | Monocentric, outpatients | Stable state | 49 Bx patients +9 healthy subjects | Immunoassay (?) | NE levels (μg x L): colonized patients 231 (15–2930); not colonized patients 15 (8–2280); healthy subjects 34 (9–44) | BAL | NE higher in Bx than in healthy subjects; Correlation with neutrophils, IL8 and TNFα in BALF; Correlation with bacterial chronic respiratory infection. |
| Stockley, 2001 [65] | Cross-sectional | Monocentric, outpatients | Stable state | 14 Bx patients +9 smokers | Spectrophotometry, MSAPN substrate Elisa (in-home assay) | NE levels (μM): sputum colour value-3 0.006 ± 1.0; sputum colour value-7 4.14 ± 1.0 | Sputum | Correlation with sputum macroscopic appearance; Correlation with MPO and 24 h sputum volume; Inverse correlation with A1AT |
| Zheng, 2001 [59] | Cross-sectional | Monocentric, outpatients | Stable state | 14 Bx patients + 15 healthy subjects | Anti-NE antibodies | Median neutrophils x mm-2: Bx patients 608 (101–1013); healthy subj. 127 (24–630) | Endobronchial biopsies | NE higher in bronchiectatic lamina propria than in healthy subjects |
| Vandevier, 2002 [58] | Prospective | Monocentric, outpatients | Exacerbation | 6 Bx patients in a cohort of 18 chronic respiratory diseases | Spectrophotometry | NE levels (U x mL): Bx patients 1; CF 3 | Sputum | NE higher in Bx; NE as cause of delay in apoptotic cell clearance |
| Chan, 2003 [12] | Cross-sectional | Monocentric, outpatients | Stable state | 10 Bx patients | Spectrophotometry | NE activity range (mM): 0.9–12 | Sputum | NE not only as free but complexed with polyanionic partners (syndecan-1) and A1AT |
| Watt, 2004 [72] | Prospective | Monocentric, outpatients | Exacerbation | 15 Bx patients + 10 healthy subjects | Kinetic assays (?) | NE levels (ng x mL): after atb –73.451 (135,495–12,303) | Sputum | NE reduction after short-term antibiotic therapy |
| Chan, 2009 [61] | Cross-sectional | Monocentric, outpatients | Stable state | 12 Bx patients | Spectrophotometry, MSAPN substrate ELISA (in-home assay) | NE activity (mM): 1.3 (1–2) | Sputum | NE complexed with syndecan-1; Description of protease/anti-protease balance |
| Murray, 2010 [77] | RCT | Monocentric, outpatients | Stable state | 65 Bx patients | Elastin-agarose diffusion plate (in-home assay) | NE activity gentamicin group vs placebo: (U x mg): baseline 3.6 (0–17.6) vs 4.1 (0–19); 3-month 0 (0–0) vs 0 (0–20.4) | Sputum | NE reduction after 3-month inhaled gentamicin |
| Author and year | Study design | Setting | Clinical stability | Sample size | Assay manufacturer (methods) | Quantitative findings | Biological matrix | Major results |
|----------------|--------------|---------|--------------------|-------------|----------------------------|----------------------|-------------------|---------------|
| Chalmers, 2012 [67] | Prospective | Monocentric, outpatients | Stable state | 385 Bx patients | ELastin-agarose diffusion plate (in-home assay) | 6-month: 0 (0–2.9) vs 0 (0–29.1); 9-month: 0 (0–7.6) vs 0.9 (0–19.4); 12-month: 0 (0–18) vs 1.8 (0.17–16); 15-month: 7.1 (0–58) vs 2.8 (0.9–18.2) | Sputum | Correlation with bacterial load and radiological severity |
| Mandall, 2013 [73] | Prospective | Monocentric, outpatients | Stable state | 163 Bx patients | Spectrophotometry | NE activity (U x mL): GERD group 5; non-GERD group 3 | Sputum | Correlation with GERD |
| Stockley, 2013 [55] | RCT | Multicentric, outpatients | Stable state | 38 Bx patients | Custom-made immunoassay (in-home assay) for both NE and desmosine | NE activity AZD9668 group vs placebo (μM x L): baseline 2454 vs 728; end of treatment 15.92 vs 7.49 | Sputum | NE reduction after 28-day of oral AZD9668 No difference in desmosine between AZD9668 and placebo |
| Goeminne, 2014 [66] | Cross-sectional | Monocentric, outpatients | Stable state | 49 Bx patients + 12 healthy subjects | Enzymatic assay | NE activity (μg x mL): Bx patients 15 (3–23); healthy subject 0.8 (0.4–1.2) | Sputum | Correlation with TNFA, CXCL8 and MMP-9 Inverse correlation with FVC |
| Liu, 2014 [14] | RCT | Monocentric, outpatients | Stable state | 43 Bx patients | ELISA (in-home assay) | Quantitative findings only reported as figures | Sputum | NE reduction after 6-month roxythromicin |
| Aliberti, 2016 [70] | Prospective | Multicentric, outpatients | Stable state | 1145 Bx patients | different assays according to different centers | Quantitative findings only reported as figures | Sputum | Correlation with P. aeruginosa cluster and ‘Other chronic infection’ cluster |
| Chalmers, 2016 [17] | Prospective | Stable state | Exacerbation | 381 Bx patients | Immunocassay (ProAxis LTD) Kinetic assay (Sigma Aldrich) LC-MS for desmosine | NE levels (μg x mL): baseline 0.39 (0–23.3); onset of exacerbation 57.0 (3.3–143); after 14-day abx 0 (0–125.8); 1-month later 1.3 (0–20.9) | Sputum | Correlation with BSI, MRC, FEV1, bacterial load, radiological severity; Correlation with higher exacerbation rate, FEV1 decline, all-cause mortality during 3-year follow up; NE increase during exacerbations and NE reduction after short-term antibiotic therapy; Serum desmosine is associated with age and disease severity |

Definitions: abx antibiotics, AAT alpha-1 anti-trypsin, BAL broncho-alveolar lavage, Bx bronchiectasis, DES desmosine, NE neutrophil elastase, SLAPN succinyl-trialanine-nitroanilide, SAAVNA succinyl-Ala-Ala-Ala-Pro-Val-nitroanilide, HPCE high-performance capillary electrophoresis, LC-MS liquid chromatography-mass spectrometry
Moreover, NE has been shown to progressively increase with increasing bacterial load in sputum. Chalmers also reported on a strong association between sputum bacterial load and a cluster of inflammatory mediators in a cohort of 434 bronchiectasis patients [16, 67]. Finally, high levels of NE have been documented in special phenotypes of bronchiectasis patients, such as those with chronic infection with both P. aeruginosa and other bacteria [68–70].

As a marker of airway inflammation, NE also increases during exacerbations and decreases after a short course of oral antibiotic treatment [6, 67, 71, 72]. These data suggest that NE may act as marker of airway inflammation both in stable patients and during exacerbations. A correlation between gastroesophageal reflux disease (GERD) and higher levels of NE is also reported [73].

**NE as a predictor of clinical outcomes or response to treatment**

The identification of a biomarker to assess disease severity and predict progression and outcomes is still an unmet need in bronchiectasis [51]. In the past decades, several experiences showed that NE is associated with clinical outcomes in different bronchiectasis cohorts [66, 74, 75]. Tsang and coworkers showed a correlation between sputum elastase, radiological involvement, and functional markers in a sample of 30 bronchiectasis patients [75]. However, the heterogeneity of measurement assays for NE among different cohorts and the lack of relevant follow-up periods may have affected the findings. Recently, NE underwent a prospective validation in a large cohort of patients followed over 3 years. This sample was divided into three groups according to negative, intermediate, and high elastase activity levels. NE activity was independently associated with lung function decline over 3 years with a loss of 56.4 ml per year in the high activity group (+20.8 ml in comparison with negative-NE group). In addition, NE was also independently associated with the risk of future exacerbations, shorter time to next exacerbation, and all-cause mortality [17].

In a recent evaluation of clinical phenotypes, the phenotype of patients with chronic infection with P. aeruginosa or other bacteria was associated with both higher NE concentrations and worse clinical outcome [70]. This finding is consistent with a meta-analysis by Finch which showed that P. aeruginosa chronic infection is associated with a threefold increased risk of death and an increase in hospital admissions and exacerbations [76].

Future clinical trials are needed to validate cut-off of NE activity and implement NE as a useful biomarker in the clinical management of bronchiectasis patients. Local or systemic antibiotic therapy and consequent reduction of bacterial load has been hypothesized to decrease sputum NE levels. Previous findings suggest that short oral courses of antibiotic therapy are effective in reducing NE activity in sputum [6, 67, 71]. Chalmers and Murray proved that long-term nebulized gentamycin significantly reduces free elastase activity in sputum, as well as sputum MPO levels and bacterial load [67, 77].

Roxithromycin treatment may reduce sputum NE in bronchiectasis patients as recently demonstrated by Liu in an open-label 6-month study. These findings demonstrate that macrolide therapy may be beneficial in bronchiectasis and may contribute to the understanding of underlying mechanisms [14, 78].

Selected anti-inflammatory drugs have also been tested as indirect modulators of neutrophilic inflammation in bronchiectasis. In a study by Llewellyn-Jones, a 4-week treatment with indomethacin appeared to have no effect on lung inflammation, as assessed by no significant difference in neutrophil and NE activity within the sputum [15].

**NE as a target of treatment**

Since NE is a major driver of neutrophilic inflammation in bronchiectasis, it has been proposed to tailor treatment aimed to its direct or indirect inhibition, see Fig. 2. AZD9668 is a NE inhibitor previously investigated in chronic respiratory diseases, including COPD and CF, with inconclusive results [34, 44, 45]. In a small phase II double-blind trial conducted in 10 different centres, 38 patients were randomized to 4 weeks of oral AZD9668 twice daily. AZD9668 increased FEV1 (by about 100 mL) and slowed vital capacity (by about 130 mL) compared with the placebo group. A trend in reduction of most inflammatory biomarkers was also reported (IL-6 and IL-8). There were no differences between AZD9668 and placebo arms regarding sputum quantity, symptoms, and quality of life. The Authors suggested larger studies of longer duration to assess beneficial effects [55, 79].

BAY 85–8501 is a selective NE inhibitor that has shown efficacy in pre-clinical pharmacological and animal models [80]. A phase II randomized parallel group study assessed the safety and tolerability of 28-day oral administration of BAY 85–8501 in 94 bronchiectasis patients. BAY 85–8501 was generally well tolerated and there were no significant changes in lung function, 24 h sputum quantity, NE activity and concentration, and other biomarkers including urine desmosine [81]. Short duration of treatment and inadequate drug concentration at the target site may be the cause of this lack of efficacy. Regarding this last point, it is reasonable that the inhaled approach instead of the oral administration could allow reaching higher lung concentrations with limited systemic exposure and consequent side effects, thus permitting to counteract that elevated amount of active NE found in the patient’s airways.

With this rationale, CHF6333 is the first inhaled NE inhibitor under development for the treatment of NE-
driven lung diseases as dry powder inhaler. In in vitro assays, CHF6333 is highly potent in inhibiting human NE (IC_{50} = 0.2 nM) with good selectivity against other proteases. In addition, CHF6333 significantly reduces lung neutrophil recruitment induced by cigarette smoke exposure in mice and reduces both lung tissue infection and inflammation when administered intratracheally to *P. aeruginosa* lung infected rats for 7 days [82].

A phase I trial to investigate safety and pharmacokinetics on healthy male subjects is still in phase of recruitment (clinicaltrial.gov ID NCT03056326).

**Conclusions**

Sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and during exacerbations and local or systemic antibiotic treatment. NE has also been associated with risk of exacerbation, time to next exacerbation and all-cause mortality. Inhibition of NE as a specific target of treatment in bronchiectasis is at a very early stage. Future interventional studies should evaluate safety and efficacy for new molecules and formulations.

**Availability of data and material**

Not applicable.

**Funding**

Not applicable.

**Authors’ contributions**

Conception and design: SA, FB. Performed research and paper revision: AG, FA, GS. Analysis and Interpretation: AG, FA, GS, SA. Drafting the manuscript: AG, FA, PT, DM, MAC. All authors participated in writing and revising the article prior to submission. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

SA reports grant support from AstraZeneca, Bayer Healthcare, Pfizer Ltd. and GlaxoSmithKline. FB reports research grants from Boehringer Ingelheim, Chiesi, Zambon, and Pfizer, congress lecture fees from Boehringer Ingelheim, Guidotti-Malesci, Menarini, GSK, Chiesi, Pfizer and Novartis, and consultancy fees from AstraZeneca, Menarini, Mundipharma, Novartis, GSK, Teva and Pfizer; DM and MAC are employees of Chiesi Farmaceutici.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

### Fig. 2 Neutrophil elastase: mechanisms of action and treatment targets in bronchiectasis

Definitions: NE = neutrophil elastase; A1AT = alpha-1 anti-trypsin; NSAIDS = non-steroidal anti-inflammatory drugs.
Author details
1. Department of Pathophysiology and Transplantation, University of Milan, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 2. Department of Clinical Sciences and Community Health University of Milano, Paediatric Highly Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 3. Department of Biomedical Sciences, Clinical Epidemiology and Medical Statistics Unit, University of Sassari, Sassari, Italy. 4. Corporate Pre-Clinical R&D, Chiesi Farmaceutici SpA, Parma, Italy. 5. Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.

Received: 22 September 2017 Accepted: 2 December 2017

Published online: 19 December 2017

References
1. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011 Jul 25;11(8):519–31.
2. Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. 2016 May 1;127(18):2173–81.
3. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989 Feb 3;320(6):365–76.
4. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980 Jul 3;303(1):27–34.
5. Tosi MF, Zakem H, Berger M. Neutrophil elastase degrades CB3I on opsonized pneumococci as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990 Jul;86(1):300–8.
6. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax. 1984 Sep;39(9):663–7.
7. Amtani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, Stockley RA, Cole PJ. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteins on human respiratory epithelium. Am J Resp Cell Mol Biol. 1991 Jan;4(1):26–32.
8. Cech P, Leherer RI. Phagolysosomal pH of human neutrophils. Blood. 1984 Jun 15;63(1):188–95.
9. Owen CD, Campbell MA, Sannes PL, Boukedes SS, Campbell J. Cell surface- bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol. 1995 Nov;131(3):775–89.
10. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS. Neutrophil gelatinase B potentiates interleukin-10 and tumour-necrosis factor complexes. J Cell Biol. 2004 Oct 18;165(4):885–90.
11. Rajak P, Fung MH, Yee LM, Chen M, Wang W, Sacks HS, Weiss DS. Neutrophil gelatinase B regulates neutrophil activation and degranulation. Proc Natl Acad Sci U S A. 2007 Sep 5;104(35):14100–5.
12. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O. Linkage of neutrophil serine proteases and decreased surfactant protein-A levels in inflammatory lung disease. Thorax. 2004 May;59(5):418–23.
13. van den Steen PE, Proost P, Wuyts A, Van Damme J, Opperdoes FR. Neutrophil gelatinase regulates monocyte CC-chemokine expression in response to TNF-alpha. Cell Immunol. 2005 May 15;244(2):188–91.
14. Ghyselinck N, Delalande M, Collon D, Rosset P, Gobert M, Chidiac M, de Wever N, Desnuelle P. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis. 2004 Oct 1;190(7):1245–53.
15. Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, O'Neill SJ, Taggart CC, McElvaney NG. Elafin, an elastase-specific inhibitor, is cleared by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem. 2008 Nov 21;283(47):32377–85.
16. Doring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol. 1995 May 1;154(9):4842–30.
17. Hunt O, Latsari P, Horikd F, Marco R, Virdal A, Rudolph C, Weishnisch M, Krauss-Etschmann S, Kolber R, Reinhardt D, Roscher AA, Roos D, Grie C. Measles of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis in lung disease. Nat Med. 2007 Dec;13(12):1423–30.
18. Gentzsch M, Dang H, Dang Y, Garcia-Caballero A, Suchindran H, Boucher RC, Stutts MJ. The cystic fibrosis transmembrane conductance regulator impede proteolytic stimulation of the epithelial Na+ channel. J Biol Chem. 2010 Oct 15;285(42):32277–32.
19. Le Gars M, Descamps D, Roussel D, Sauvageau E, Guillot L, Ruffin M, Tabary O, Hong SS, Boulanger P, Paulais M, Malleret L, Belaaouaj A, Edelman A, Huerre M, Chignard M, Sallenave JM. Neutrophil elastase degrades fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med. 2013 Jan 15;187(2):170–9.
20. Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J. 2012 Oct;40(4):969–76.
21. Gieze M, Latsari P, Kappler M, Weckerle K, Heinzmaier T, Bernhardt T, Hartl D. alpha-antitrypsin inhibition reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007 Feb;29(2):240–50.
22. Salmensuu D, Sanna A, Vesteras C, Kristoanen S, Galicagi PG, Fabbri LM, Maestrelli P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996 Mar;51(3):267–71.
23. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009 Dec;41(6):631–8.
and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999 Jun;13(6):1371–9.

79. Gunawardena KA, Gullstrand H, Perrett J. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. Int J Clin Pharmacol Ther. 2013 Apr;51(4):288–304.

80. von Nussbaum F, Li VM, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Melborn D, Mittendorf J, Rosentreter U, Schäfer M, Schärer S, Schamberger J, Telan LA, Tersteegen A. Freezing the bioactive conformation to boost potency: the identification of BAY 85-8501, a selective and potent inhibitor of Neutrophil Elastase for pulmonary diseases. ChemMedChem. 2015 Jul;10(7):1163–73.

81. Watz H, Pedersen F, Kirsten A, Nagelschmitz J, Bandel TJ, Schwers S, Rabe K. Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis. ERS International Congress 2016.

82. Miglietta D, Camini C, Puviani V, Finch H, Fox C, Fitzgerald M, Patacchini R, Civelli M, Villetti G. Pharmacological characterization of CHF6333, a novel potent inhaled inhibitor of neutrophil elastase. ERS International Congress 2016.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit